{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:11:07Z","timestamp":1764936667315,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clml.2013.03.014","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T18:18:15Z","timestamp":1370456295000},"page":"410-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Tetsuichi","family":"Yoshizato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.03.014_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/S0962935193000018","article-title":"Biological significance of soluble IL-2 receptor","volume":"2","author":"Caruso","year":"1993","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.clml.2013.03.014_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0277-5379(90)90253-P","article-title":"The biological significance of soluble interleukin-2 receptors in solid tumors","volume":"26","author":"Lissoni","year":"1990","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2013.03.014_bib3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1164\/ajrccm\/139.4.1036","article-title":"Prolonged elevations of soluble interleukin-2 receptors in tuberculosis","volume":"139","author":"Brown","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.clml.2013.03.014_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0090-1229(89)90140-2","article-title":"Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases","volume":"50","author":"Manoussakis","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.clml.2013.03.014_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/aid.1988.4.115","article-title":"Elevated soluble interleukin-2 receptor levels in serum of human immunodeficiency virus infected populations","volume":"4","author":"Reddy","year":"1988","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.clml.2013.03.014_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.2830460304","article-title":"Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms","volume":"46","author":"Nakase","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.03.014_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","article-title":"The soluble interleukin-2 receptor: biology, function, and clinical application","volume":"113","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2013.03.014_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy","volume":"20","author":"Ennishi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2013.03.014_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00432-004-0600-9","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index","volume":"131","author":"Goto","year":"2005","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.014_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2009.01167.x","article-title":"Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma","volume":"100","author":"Morito","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2013.03.014_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190802108888","article-title":"Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy","volume":"49","author":"Oki","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.03.014_bib12","first-page":"600","article-title":"Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Ralpha) in patients with non-Hodgkin's lymphoma","volume":"30","author":"Jo","year":"2010","journal-title":"Korean J Lab Med"},{"key":"10.1016\/j.clml.2013.03.014_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A\u00a0high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.03.014_bib14","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R alpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.014_bib15","first-page":"170","article-title":"Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study [in Japanese]","volume":"43","author":"Ohno","year":"2002","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.clml.2013.03.014_bib16","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"Chan","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.014_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1440-1827.2007.02207.x","article-title":"Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006","volume":"58","author":"Aoki","year":"2008","journal-title":"Pathol Int"},{"key":"10.1016\/j.clml.2013.03.014_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2005.11.003","article-title":"Current controversies in follicular lymphoma","volume":"20","author":"Aurora","year":"2006","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2013.03.014_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2013.03.014_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.03.014_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/07853890009011772","article-title":"Function of C-reactive protein","volume":"32","author":"Du Clos","year":"2000","journal-title":"Ann Med"},{"key":"10.1016\/j.clml.2013.03.014_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clml.2013.03.014_bib23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.014_bib24","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.014_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2249.2000.01136.x","article-title":"Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers","volume":"119","author":"Araki","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clml.2013.03.014_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.7326\/0003-4819-109-4-274","article-title":"Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy","volume":"109","author":"Marcon","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2013.03.014_bib27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood.V70.5.1530.1530","article-title":"Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity","volume":"70","author":"Chilosi","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.014_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","article-title":"Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study","volume":"60","author":"Charbonneau","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.clml.2013.03.014_bib29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.humpath.2005.12.005","article-title":"Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?","volume":"37","author":"Bosga-Bouwer","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2013.03.014_bib30","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.03.014_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2013.03.014_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.03.014_bib33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.03.014_bib34","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by\u00a0the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:52Z","timestamp":1761870232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S2152265013001146"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}